COMPOSITION
Sii Measles Vaccine (M-VAC™)
contains live attenuated measles virus (Edmonston Zagreb Strain)
propagated on Human Diploid Cells (HDC). Each dose of 0.5 ml
contains not less than 1000 CCID50 of Measles virus
on reconstitution with the diluent provided.
INDICATION
Sii Measles Vaccine (M-VAC™) is indicated for immunisation
of all susceptible children against measles. It is recommended
to be given to children at 9 months of age, or as soon as thereafter,
to protect against measles in early life. Immunisation against
measles is particularly important for institutionalized children
and for children who may be malnourished or subject to chronic
diseases such as heart disease, cystic fibrosis, asthma, tuberculosis
or other chronic pulmonary disorders.
DIRECTIONS FOR USE
Reconstitute the freeze dried vaccine by adding : 0.5 ml
of the diluent (sterile water for injection) to the single-dose
vial by using sterile disposable syringe and needle. With gentle
shaking the dried cake is easily dissolved. After reconstitution
the vaccine should be used immediately. A single dose of 0.5
ml should be administered by deep subcutaneous injection into
the upper arm.
The reconstituted vaccine must be used
immediately otherwise it should be discarded.
REACTIONS
Some
mild reactions may occur such as marginal temperature rise
in 5% to 6% of the vaccinated children, mild rash in 1%
to 2% children, occasionally mild rash and slight gastric
disorders or short-lived rhinopharyngitis. Fever or rash,
or both, generally appear between the 5th and the 12th day
after vaccination and last for one to two days.
CONTRAINDICATIONS
It is particularly
important to immunize children suffering from malnutrition.
Low-grade fever, mild respiratory infections or diarrhoea,
and other minor illness should not be considered as contraindications
to immunisation.
Only the following should be regarded as contraindications
:
-
Febrile state,
-
Acute infectious diseases,
-
Severe diseases of
the hematopoietic system,
-
Severe impairment
of the renal function,
-
Decompensated heart
diseases,
-
States of reduced
immunity, either congenital or therapeutically acquired
through irradiation and use of corticosteroid
or cytostatic drugs,
-
States of reduced
immunity, following the transplantation of an organ,
-
Diseases and disorders
of the central nervous system,
-
Within three months
following the administration of gammaglobulin or blood-transfusion,
-
Within six months
following exchange transfusion,
-
Pregnancy.
ADVANTAGES
Sii Measles Vaccine (M-VAC™) can also be given to the
patients who are allergic to egg protein or neomycin because
it is prepared on Human Diploid Cells and does not contain
neomycin.
STORAGE
Sii Measles Vaccine (M-VAC™) should be stored in a dark
place below 8°C. Diluent should not be frozen and should
be stored in a clean place away from heat and sunlight.
PRESENTATION
Sii Measles Vaccine (M-VAC™) is presented as lyophilised
vaccine in a pack containing one dose vial plus one ampoule
of sterile water for injection (0.5 ml); sterile disposable
syringe and needle supplied separately.
Sii Measles Vaccine (M-VAC™)
fulfils the relevant requirements of W.H.O.
|
MOST IMPORTANT
WARNING
|
| Please ensure that the vaccine is administered
by subcutaneous route only. In rare cases anaphylactic
shock may occur in susceptible patient and for such emergency
please keep handy 1:1000 adrenaline injection ready to
be injected intramuscularly. This will help in tackling
the anaphylactic shock/reaction effectively. |
|
